Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
1.300
+0.022 (1.72%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Lyra Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 2 | 14 | 275 | 100 | 57 | 147 | |
| Market Cap Growth | -82.86% | -95.09% | 175.61% | 76.26% | -61.52% | - | |
| Enterprise Value | 12 | -3 | 179 | -9 | 0 | 68 | |
| Last Close Price | 1.28 | 10.32 | 262.00 | 157.00 | 218.00 | 570.00 | |
| PS Ratio | 3.79 | 8.81 | 176.79 | 73.32 | 198.95 | - | |
| PB Ratio | - | 1.17 | 3.08 | 1.24 | 1.65 | 1.98 | |
| P/TBV Ratio | - | 1.17 | 3.08 | 1.24 | 1.65 | 1.98 | |
| EV/Sales Ratio | 19.33 | - | 115.00 | - | 0.97 | - | |
| Debt / Equity Ratio | -7.25 | 2.97 | 0.30 | 0.03 | 0.04 | 0.03 | |
| Net Debt / Equity Ratio | -2.15 | -0.53 | -0.85 | -1.18 | -1.29 | -0.97 | |
| Net Debt / EBITDA Ratio | -0.29 | 0.10 | 1.16 | 1.77 | 1.04 | 3.26 | |
| Net Debt / FCF Ratio | -0.27 | 0.09 | 1.18 | 2.20 | 1.52 | 3.15 | |
| Asset Turnover | 0.01 | 0.02 | 0.01 | 0.02 | 0.00 | - | |
| Quick Ratio | 2.33 | 3.21 | 5.24 | 6.77 | 2.51 | 15.27 | |
| Current Ratio | 2.43 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | |
| Return on Equity (ROE) | -404.48% | -184.99% | -73.67% | -96.08% | -79.98% | -54.09% | |
| Return on Assets (ROA) | -33.08% | -36.33% | -32.43% | -41.70% | -40.18% | -28.98% | |
| Return on Capital Employed (ROCE) | -94.70% | -113.10% | -53.30% | -57.60% | -119.10% | -29.20% | |
| Earnings Yield | -1450.23% | -691.58% | -22.76% | -55.31% | -76.74% | -15.02% | |
| FCF Yield | -1501.29% | -535.50% | -23.36% | -43.58% | -51.51% | -15.55% | |
| Buyback Yield / Dilution | -12.03% | -30.74% | -64.72% | -132.83% | -51.17% | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.